[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"grant-mrc-ukri-chemical-biological-radiological-and-nuclear-cbrn--2027-01":3,"similar-mrc-ukri-chemical-biological-radiological-and-nuclear-cbrn--2027-01":37},{"id":4,"name":5,"funder":6,"link":7,"budget":8,"budget_min_eur":9,"budget_max_eur":10,"deadline":11,"deadline_note":12,"duration":13,"trl":9,"relevance":9,"why_relevant":9,"early_career":14,"consortium":15,"first_seen":16,"last_updated":9,"update_note":9,"status":17,"stages":18,"call_frequency":9,"next_call_expected":9,"source_url":7,"created_at":19,"updated_at":20,"last_seen_at":19,"eligible_countries":21,"description":23,"seo_summary":24,"recurring_round":14,"canonical_id":4,"links":25},"mrc-ukri-chemical-biological-radiological-and-nuclear-cbrn--2027-01","Chemical, Biological, Radiological and Nuclear (CBRN) Medical Countermeasures R&D","MRC (UKRI)","https:\u002F\u002Fwww.ukri.org\u002Fopportunity\u002Finvite-only-chemical-biological-radiological-and-nuclear-cbrn-medical-countermeasures-rd\u002F","Up to £4M FEC (MRC funds 80%)",null,4680000,"2027-01-20T00:00:00.000Z","16:00 UK time","Up to 30 months",false,"No - individual applicant, hosted by UK based eligible research organisation; project partners may contribute but cannot be project lead","2026-10-18T00:00:00.000Z","open","Invite-only: requires successful Expression of Interest before invited full application","2026-10-18T08:09:38.708Z","2026-10-18T08:10:58.215Z",[22],"GB","Invite-only funding opportunity for pre-clinical and early translational research developing medical countermeasures for CBRN threats, from prototype development through early-phase clinical trials (up to phase 2a). Applicant must be employed by a UK-based eligible research organisation; international and commercial organisations cannot lead or co-lead.","{\"summary\":\"This MRC (UKRI) call funds pre-clinical and early translational research developing medical countermeasures for chemical, biological, radiological and nuclear (CBRN) threats, covering work from prototype development through early-phase clinical trials up to phase 2a. It offers up to £4M full economic cost (MRC covers 80%) over projects lasting up to 30 months, and is open only to individual applicants employed at a UK-based eligible research organisation. Entry is invite-only: applicants must first submit an Expression of Interest and be invited to submit a full application.\",\"meta_description\":\"MRC funds CBRN medical countermeasure R&D up to £4M FEC over 30 months, invite-only via Expression of Interest, UK researchers only, from MRC (UKRI).\",\"who_should_apply\":[\"Researchers employed by a UK-based eligible research organisation\",\"Individual applicants leading pre-clinical or early translational projects (no joint lead)\",\"Projects spanning prototype development through early-phase (up to phase 2a) clinical trials\",\"Teams with potential project partners, including commercial or international collaborators, who can contribute but not lead\",\"Researchers working on chemical, biological, radiological or nuclear threat countermeasures\"],\"key_dates\":[\"Expression of Interest deadline: 20 January 2027, 16:00 UK time\",\"Invite-only full application follows a successful Expression of Interest\",\"Project duration up to 30 months\"],\"tips\":[\"Treat the Expression of Interest as the real gatekeeper, only successful EOIs are invited to submit a full application, so front-load feasibility and threat relevance there.\",\"Clarify project partner roles early: international and commercial organisations can contribute funding or expertise but cannot be named as lead or co-lead.\",\"Since MRC funds 80% FEC, confirm your host institution can cover the remaining 20% before committing to the EOI.\"],\"faq\":[{\"q\":\"How much funding does the MRC CBRN Medical Countermeasures call provide?\",\"a\":\"Up to £4M full economic cost, with MRC funding 80% of that amount.\"},{\"q\":\"Is this MRC CBRN call open to direct applications?\",\"a\":\"No, it is invite-only, applicants must first submit a successful Expression of Interest before being invited to apply in full.\"},{\"q\":\"Can international or commercial organisations lead a project in this call?\",\"a\":\"No, the lead applicant must be employed by a UK-based eligible research organisation, though international and commercial organisations can participate as project partners.\"},{\"q\":\"How long can a funded CBRN medical countermeasures project run?\",\"a\":\"Projects can run for up to 30 months.\"},{\"q\":\"What stage of research does this MRC call fund?\",\"a\":\"It funds pre-clinical and early translational research, from prototype development through early-phase clinical trials up to phase 2a.\"}],\"tags\":[\"cbrn-threats\",\"medical-countermeasures\",\"mrc\",\"ukri\",\"translational-research\",\"clinical-trials\",\"uk-only\",\"invite-only\"]}",{"matchedProgram":9,"resourceSlug":26,"relatedGuides":27,"countryHubs":28,"domainHubs":32,"closingMonth":33,"hasRelated":36,"hasBrowseRelated":36},"ukri",[],[29],{"slug":30,"demonym":31},"gb","UK researchers",[],{"slug":34,"label":35},"2027-01","January 2027",true,{"grants":38},[39,43,48,53,57],{"id":40,"name":5,"funder":6,"deadline":41,"budget":42},"mrc-ukri-chemical-biological-radiological-and-nuclear-cbrn--2026-10","2026-10-20T00:00:00.000Z","Up to £4M (80% FEC)",{"id":44,"name":45,"funder":6,"deadline":46,"budget":47},"mrc-proof-of-concept-2026-11","Proof of Concept","2026-11-18T00:00:00.000Z","No limit stated; 80% FEC funded",{"id":49,"name":50,"funder":6,"deadline":51,"budget":52},"mrc-ukri-mrc-proof-of-concept-2026-11","MRC Proof of Concept","2026-11-04T00:00:00.000Z","No limit stated; 80% FEC funded (100% for permitted exceptions)",{"id":54,"name":55,"funder":6,"deadline":56,"budget":9},"mrc-experimental-medicine-2026","Experimental Medicine","2027-04-14T00:00:00.000Z",{"id":58,"name":59,"funder":60,"deadline":9,"budget":9},"cancer-research-uk-drug-development-project-2026","Drug Development Project","Cancer Research UK"]